Literature DB >> 18022329

Identification and analysis of human RCAN3 (DSCR1L2) mRNA and protein isoforms.

Federica Facchin1, Silvia Canaider, Lorenza Vitale, Flavia Frabetti, Cristiana Griffoni, Luca Lenzi, Raffaella Casadei, Pierluigi Strippoli.   

Abstract

Human RCAN3 (Regulator of calcineurin 3; previously known as DSCR1L2, Down syndrome critical region gene 1-like 2) is a five-exon gene mapped on chromosome 1 and belongs to the human RCAN gene family which also includes RCAN1 and RCAN2. The novel denomination RCAN for genes and proteins, instead of DSCR1L (Down syndrome critical region gene 1-like) has recently been widely discussed. The aim of the present work was to perform a multiple approach analysis of five RCAN3 mRNA and encoded protein isoforms, two of which have been identified for the first time in this research. The two new RCAN3 mRNA isoforms, RCAN3-2,4,5, which lacks exon 3, and RCAN3-2,3,5, which lacks exon 4, were identified during RCAN3 RT-PCR (reverse transcription-polymerase chain reaction) cloning, the product of which unexpectedly revealed the presence of five isoforms as opposed to the three previously known. In order to analyze the expression pattern of the five RCAN3 mRNA isoforms in seven different human tissues, a quantitative relative RT-PCR was performed: interestingly, all isoforms are present in all tissues investigated, with a statistically significant constant prevalence of RCAN3 isoform (the most complete, "reference" isoform). The RCAN3 locus expression level was comparable in all seven tissues analyzed, considering all isoforms, which indicates a ubiquitous expression of this human RCAN family member. To date two possible interactors have been described for this protein: human cardiac troponin I (TNNI3) and calcineurin. Here we report the interaction between the new RCAN3 variants and TNNI3, demonstrated by both yeast cotransformation and by the GST (glutathione-sepharose transferase) fusion protein assay, as was to be expected from the presence of exon 2 whose product has been seen to be sufficient for binding to TNNI3.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18022329     DOI: 10.1016/j.gene.2007.10.006

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  6 in total

1.  Aberrant behavioral sensitization by methamphetamine in junctophilin-deficient mice.

Authors:  Shigeki Moriguchi; Miyuki Nishi; Yuzuru Sasaki; Hiroshi Takeshima; Kohji Fukunaga
Journal:  Mol Neurobiol       Date:  2014-05-22       Impact factor: 5.590

Review 2.  Calcineurin Signalling in Astrocytes: From Pathology to Physiology and Control of Neuronal Functions.

Authors:  Dmitry Lim; Laura Tapella; Giulia Dematteis; Maria Talmon; Armando A Genazzani
Journal:  Neurochem Res       Date:  2022-09-09       Impact factor: 4.414

3.  Complexity of bidirectional transcription and alternative splicing at human RCAN3 locus.

Authors:  Federica Facchin; Lorenza Vitale; Eva Bianconi; Francesco Piva; Flavia Frabetti; Pierluigi Strippoli; Raffaella Casadei; Maria Chiara Pelleri; Allison Piovesan; Silvia Canaider
Journal:  PLoS One       Date:  2011-09-22       Impact factor: 3.240

Review 4.  Regulator of Calcineurin (RCAN): Beyond Down Syndrome Critical Region.

Authors:  Sun-Kyung Lee; Joohong Ahnn
Journal:  Mol Cells       Date:  2020-08-31       Impact factor: 5.034

5.  The vertebrate RCAN gene family: novel insights into evolution, structure and regulation.

Authors:  Eva Serrano-Candelas; Domènec Farré; Álvaro Aranguren-Ibáñez; Sergio Martínez-Høyer; Mercè Pérez-Riba
Journal:  PLoS One       Date:  2014-01-20       Impact factor: 3.240

6.  Giraffe genome sequence reveals clues to its unique morphology and physiology.

Authors:  Morris Agaba; Edson Ishengoma; Webb C Miller; Barbara C McGrath; Chelsea N Hudson; Oscar C Bedoya Reina; Aakrosh Ratan; Rico Burhans; Rayan Chikhi; Paul Medvedev; Craig A Praul; Lan Wu-Cavener; Brendan Wood; Heather Robertson; Linda Penfold; Douglas R Cavener
Journal:  Nat Commun       Date:  2016-05-17       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.